10 de diciembre de 2019
  • Lunes, 9 de Diciembre
  • Sábado, 7 de Diciembre
  • Viernes, 6 de Diciembre
  • 9 de diciembre de 2009

    Important Progress in Treatment of Early and Late Stage Breast Cancer With Herceptin, Avastin and T-DM1 (1)


    - 5-years of follow-up data will be presented from these pivotal phase
    III studies that have already shown efficacy in patients when adding 12
    months of Herceptin to standard therapy.
    - Both studies were seeking to answer questions the medical community has
    been contemplating regarding the best way of giving their patients
    Herceptin treatment.
    Avastin RIBBON-2 study, second-line treatment data
    - Avastin is well established as a first-line treatment for women with
    advanced breast cancer. RIBBON-2 will report on the benefits of Avastin
    in combination with commonly used chemotherapies in the second-line
    setting where currently the only option is subsequent chemotherapy.

    T--DM1 4374 study in very advanced breast cancer

    New data from a phase II study (TDM4374) in a very advanced patient population who have exhausted other treatment options will be presented. This follows on from another phase II study (TDM4258) that was presented at ASCO 2009 which showed encouraging results in women with advanced HER2-positive breast cancer.

    In addition, further data from the phase II study BO17929 will be presented, demonstrating that the combination of pertuzumab and trastuzumab shows efficacy in patients with HER2-positive advanced breast cancer whose disease had progressed during prior treatment with Herceptin plus chemotherapy.[i] The data, which suggest that combining pertuzumab and trastuzumab may offer an effective new treatment option to patients with HER2-positive advanced breast cancer, have been accepted as a poster presentation on Saturday 12 Dec, 17:30 - 19:30, Poster Session 5, Exhibit Halls A-B.

    Details of key studies being presented:

    Herceptin N9831 study

    The study is part of the official SABCS press programme on Saturday 12 Dec., 08:00 hrs.

    [TAB]

    Dr E. Perez, Results of chemotherapy alone, with Oral

    et al sequential or concurrent addition of presentation

    trastuzumab in the NCCTG N9831 Saturday 12

    HER2-positive adjuvant breast cancer Dec, 15:00,

    trial. General

    Session 6,

    Exhibit Hall

    D.

    Herceptin BCIRG 006 study

    Dr. D. Slamon, Phase III randomized trial comparing Oral

    et al doxorubicin and cyclophosphamide followed presentation

    by docetaxel (AC à T) with doxorubicin and Saturday 12

    cyclophosphamide followed by docetaxel and Dec, 09:45,

    trastuzumab (AC à TH) with docetaxel, General

    carboplatin and trastuzumab (TCH) in Session 5,

    Her2neu positive early breast cancer Exhibit Hall

    patients: BCIRG 006 study. D.

    Avastin RIBBON-2 study

    The study is part of the official SABCS press programme on Friday 11

    Dec., 12:30 hrs.

    Dr. A. RIBBON-2: A randomized, double-blind, Oral

    Brufsky, et al placebo-controlled, phase III trial presentation

    evaluating the efficacy and safety of Friday 11

    bevacizumab in combination with Dec, 15:00,

    chemotherapy for second-line treatment of General

    HER2-negative metastatic breast cancer. Session 4,

    Exhibit Hall

    D.

    T-DM1 4374 study

    Dr. I. Krop, A phase II study of trastuzumab-DM1 Poster

    et al (T-DM1), a novel HER2 antibody-drug presentation

    conjugate, in patients previously treated Saturday 12

    with lapatinib, trastuzumab, and Dec, 07:00 -

    chemotherapy. 09:00.

    Poster

    Discussion

    7, Ballroom

    B.

    [FTAB]

    The above mentioned studies and data represent the latest results of clinical research for each treatment and are not necessarily part of the indicated licence in each country. For detailed label information, visit the website of your health authority or the EMEA website http://www.emea.europa.eu/

    In HER2-positive breast cancer, increased quantities of the HER2 protein are present on the surface of the tumour cells. This is known as 'HER2-positivity'. High levels of HER2 are present in a particularly aggressive form of the disease which responds poorly to chemotherapy. Research shows that HER2-positivity affects approximately 20-30 percent of women with breast cancer.[ii]

    The 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) takes place from 9 to 13 December 2009. Full details can be found at http://www.sabcs.org/.

    About Roche

    Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.

    In 2008, Roche had over 80'000 employees worldwide and invested almost 9 billion Swiss francs in R&D.

    The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: http://www.roche.com.

    All trademarks used or mentioned in this release are protected by law.

    Additional information

    (CONTINUA)


    Dr E. Perez, Results of chemotherapy alone, with Oral
    et al sequential or concurrent addition of presentation
    trastuzumab in the NCCTG N9831 Saturday 12
    HER2-positive adjuvant breast cancer Dec, 15:00,
    trial. General
    Session 6,
    Exhibit Hall
    D.
    Herceptin BCIRG 006 study
    Dr. D. Slamon, Phase III randomized trial comparing Oral
    et al doxorubicin and cyclophosphamide followed presentation
    by docetaxel (AC à T) with doxorubicin and Saturday 12
    cyclophosphamide followed by docetaxel and Dec, 09:45,
    trastuzumab (AC à TH) with docetaxel, General
    carboplatin and trastuzumab (TCH) in Session 5,
    Her2neu positive early breast cancer Exhibit Hall
    patients: BCIRG 006 study. D.
    Avastin RIBBON-2 study
    The study is part of the official SABCS press programme on Friday 11
    Dec., 12:30 hrs.
    Dr. A. RIBBON-2: A randomized, double-blind, Oral
    Brufsky, et al placebo-controlled, phase III trial presentation
    evaluating the efficacy and safety of Friday 11
    bevacizumab in combination with Dec, 15:00,
    chemotherapy for second-line treatment of General
    HER2-negative metastatic breast cancer. Session 4,
    Exhibit Hall
    D.
    T-DM1 4374 study
    Dr. I. Krop, A phase II study of trastuzumab-DM1 Poster
    et al (T-DM1), a novel HER2 antibody-drug presentation
    conjugate, in patients previously treated Saturday 12
    with lapatinib, trastuzumab, and Dec, 07:00 -
    chemotherapy. 09:00.
    Poster
    Discussion
    7, Ballroom
    B.

    The above mentioned studies and data represent the latest results of clinical research for each treatment and are not necessarily part of the indicated licence in each country. For detailed label information, visit the website of your health authority or the EMEA website http://www.emea.europa.eu/

    In HER2-positive breast cancer, increased quantities of the HER2 protein are present on the surface of the tumour cells. This is known as 'HER2-positivity'. High levels of HER2 are present in a particularly aggressive form of the disease which responds poorly to chemotherapy. Research shows that HER2-positivity affects approximately 20-30 percent of women with breast cancer.[ii]

    The 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) takes place from 9 to 13 December 2009. Full details can be found at http://www.sabcs.org/.

    About Roche

    Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.

    In 2008, Roche had over 80'000 employees worldwide and invested almost 9 billion Swiss francs in R&D.

    The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: http://www.roche.com.

    All trademarks used or mentioned in this release are protected by law.

    Additional information

    (CONTINUA)